<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01162889</url>
  </required_header>
  <id_info>
    <org_study_id>B2281001</org_study_id>
    <secondary_id>3243K1-1000</secondary_id>
    <nct_id>NCT01162889</nct_id>
  </id_info>
  <brief_title>Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People</brief_title>
  <official_title>Ascending Single Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ATR-107 Administered Subcutaneously And Intravenously To Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a &quot;first in human&quot; study to determine the safety and tolerability of the drug after
      single doses. Nine doses of increasing strength will be injected or infused (given into a
      vein) to 9 different groups of people. One third of the participants will be given an
      injection or infusion of placebo (sugar water). All participants will be healthy people.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First in human single dose study. Study terminated 12 October 2011. The ATR-107 Development
      team reached a recommendation to terminate further development of ATR-107 (PF-05230900). This
      was based on a number of factors, including development of anti-drug antibodies in
      approximately 70% of subjects in the First-in-Human study in healthy volunteers (B2281001).
      This recommendation is not based on adverse events observed in study B2281001.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-emergent AEs and SAEs, AEs leading to withdrawal, immunogenicity, injection and infusion reactions, and clinically significant changes in laboratory tests, vital signs and ECGs if reported.</measure>
    <time_frame>20 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameters - Cmax, Tmax, AUC(0-oo), AUClast, t 1/2, CL and Vz</measure>
    <time_frame>19 months</time_frame>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo - SC injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug dose level 1 - SC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug dose level 2 - SC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug dose level 3- SC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug dose level 4 - SC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug dose level 5 - SC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug dose level 6 - IV Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug dose level 7 - IV Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug dose level 8 - IV infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - IV infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug dose level 9 - IV infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SC Injection</intervention_name>
    <description>Single injection</description>
    <arm_group_label>Placebo - SC injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATR-107 (PF-05230900) SC Injection</intervention_name>
    <description>Single intravenous infusion, 60 minute duration</description>
    <arm_group_label>Drug dose level 1 - SC injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATR-107 (PF-05230900) SC Injection</intervention_name>
    <description>Single subcutaneous injection</description>
    <arm_group_label>Drug dose level 2 - SC injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATR-107 (PF-05230900) SC Injection</intervention_name>
    <description>Single subcutaneous injection</description>
    <arm_group_label>Drug dose level 3- SC injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATR-107 (PF-05230900) SC Injection</intervention_name>
    <description>Single subcutaneous injection</description>
    <arm_group_label>Drug dose level 4 - SC injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATR-107 (PF-05230900) SC Injection</intervention_name>
    <description>Single subcutaneous injection</description>
    <arm_group_label>Drug dose level 5 - SC injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATR-107 (PF-05230900) IV Infusion</intervention_name>
    <description>Single subcutaneous injection</description>
    <arm_group_label>Drug dose level 6 - IV Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATR-107 (PF-05230900) IV Infusion</intervention_name>
    <description>Single intravenous infusion, 60 minute duration</description>
    <arm_group_label>Drug dose level 7 - IV Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATR-107 (PF-05230900) IV Infusion</intervention_name>
    <description>Single intravenous infusion, 60 minute duration</description>
    <arm_group_label>Drug dose level 8 - IV infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV Infusion</intervention_name>
    <description>Single intravenous infusion, 60 minute duration</description>
    <arm_group_label>Placebo - IV infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATR-107 (PF-05230900) IV Infusion</intervention_name>
    <description>Single intravenous infusion, 60 minute duration</description>
    <arm_group_label>Drug dose level 9 - IV infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females of non-childbearing potential

          -  Body mass index between 17.5 to 30.5 and body weight &gt; 50 kg

        Exclusion Criteria:

          -  History of significant medical illness

          -  Positive urine drug screen or alcohol dependance

          -  Smoking &gt; 10 cigarettes per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2281001&amp;StudyName=Study%20To%20Assess%20The%20Safety%20And%20Tolerability%20Of%20Increasing%20Single%20Doses%20Of%20ATR-107%20%28PF-05230900%29%20In%20Healthy%20People</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2010</study_first_posted>
  <last_update_submitted>March 13, 2012</last_update_submitted>
  <last_update_submitted_qc>March 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>Crohn's disease</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

